COVID-19LCRCNCT05131594
Evaluating the Response of the Immune System of People With Long COVID (Post SARS-CoV-2)
An observational study of COVID-19, run by Huntington Memorial Hospital at 1 site in United States.
Trial summary
Many people who have had COVID 19 continue to experience symptoms long after they have recovered from the acute infection. This study will examine the clinical symptoms of people with "Long COVID" and measure various markers of inflammation in their blood. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- COVID-19
- How many people
- 59 participants
- Where
- 1 siteUnited States
- Study dates
- 13 Oct 2021to 21 Aug 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adult patients (18 years old or older) who enroll in Huntington Hospital's Long Covid Recovery Clinic will be offered but are under no obligation to participate in this study. Subjects will have documented previous infection with SARS-CoV2 and symptoms suggestive of post-acute sequelae of SARS-CoV2 (including but not limited to chronic fatigue, brain fog, muscle and joint pain, cardiac and pulmonary issues, or other factors related to their acute COVID-19 event).
Who may be able to join
- Enrolled in Huntington Hospital\'s Long Covid Recovery Clinic
- Documented previous infection with SARS-CoV2
- Symptoms suggestive of post-acute sequelae of SARS-CoV2 (including but not limited to chronic fatigue, brain fog, muscle and joint pain, cardiac and pulmonary issues, or other factors related to their acute COVID-19 event)
- Signed Informed Consent Form
Who cannot join
- No documented positive SARS-CoV2 serologies
- No post-acute sequelae of SARS-CoV2 symptomatology
- Incarcerated
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Immune Response to Post Acute Sequelae of SARSCoV2: A Correlation of Clinical Symptoms and Inflammatory Pathways
Many people who have had COVID 19 continue to experience symptoms long after they have recovered from the acute infection. This study will examine the clinical symptoms of people with "Long COVID" and measure various markers of inflammation in their blood.
Read the detailed description
Patients who attend the Long Covid Recovery Clinic at Huntington Hospital will be offered participation in the study. After giving written informed consent, their medical history along with a description of clinical symptoms given through an extensive questionnaire will be accessed. Venous blood will be collected as a baseline and then at follow up visits (as dictated by changes in clinical symptomatology) for evaluation of corollary immune parameters. Patients will be followed at a minimum of every 2 months for 2 years.
- Conditions
- COVID-19
- Keywords
- post-acute sequelae of SARS-CoV2, post-acute COVID-19 syndrome, long COVID
- Medical subject headings
- COVID-19, Post-Acute COVID-19 Syndrome
What is being measured
The primary outcome is the main question the study is designed to answer.
Correlation of symptomatology with inflammatory profiles in patients with Post-Acute Sequelae of SARS-CoV2 (PASC)
Do patient symptoms correlate with abnormalities in inflammatory profiles?
Measured: From onset of infection to 24 months
Identification of immunologic and inflammatory features of PASC based on results of immunologic and inflammatory assays
Are there abnormalities in immunologic and inflammatory assays unique to PASC?
Measured: From onset of infection to 24 months
Evaluation and delineation of the pathologic pathways and long-term effects of SARS-CoV2 infection
What are the pathological pathways and long-term effects of SARS-CoV2?
Measured: From onset of infection to 60 months
Identification of risks factor for PASC
What are the risk factors for PASC?
Measured: From onset of infection to 24 months
Identification of potential sites of therapeutic intervention to ameliorate symptomatology of PASC
Are there potential sites of therapeutic intervention to relieve the symptoms of PASC?
Measured: From onset of infection to 60 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Nov 2021
- Study start13 Oct 2021
- Primary completion31 Oct 2024
- Study completion21 Aug 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for COVID-19Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 59 participants (actual)
Sponsor and investigators
- Lead sponsor
- Huntington Memorial Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- San Diego Biomedical Research Institute
- Responsible party
- Sponsor
- Investigators
- Kimberly Shriner, MD, Principal investigator, Huntington Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05131594
- Sponsor's protocol ID
- Pro00054801
- Acronym
- LCRC
- Status last verified
- Sep 2026
- First submitted
- 19 Nov 2021
- Last updated
- 20 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Immune Response to Post Acute Sequelae of SARSCoV2: A Correlation of Clinical Symptoms and Inflammatory Pathways
- ClinicalTrials.gov ID
- NCT05131594
- Acronym / sponsor ID
- LCRC / Pro00054801
- Conditions
- COVID-19
- Keywords
- post-acute sequelae of SARS-CoV2, post-acute COVID-19 syndrome, long COVID
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 59 participants (actual)
- Lead sponsor
- Huntington Memorial HospitalUniversity, hospital or other
- Collaborators
- San Diego Biomedical Research Institute
- Study start
- 13 Oct 2021 (actual)
- Primary completion
- 31 Oct 2024 (actual)
- Study completion
- 21 Aug 2026 (actual)
- First posted
- 23 Nov 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Many people who have had COVID 19 continue to experience symptoms long after they have recovered from the acute infection. This study will examine the clinical symptoms of people with "Long COVID" and measure various markers of inflammation in their blood.
Detailed description
Patients who attend the Long Covid Recovery Clinic at Huntington Hospital will be offered participation in the study. After giving written informed consent, their medical history along with a description of clinical symptoms given through an extensive questionnaire will be accessed. Venous blood will be collected as a baseline and then at follow up visits (as dictated by changes in clinical symptomatology) for evaluation of corollary immune parameters. Patients will be followed at a minimum of every 2 months for 2 years.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adult patients (18 years old or older) who enroll in Huntington Hospital's Long Covid Recovery Clinic will be offered but are under no obligation to participate in this study. Subjects will have documented previous infection with SARS-CoV2 and symptoms suggestive of post-acute sequelae of SARS-CoV2 (including but not limited to chronic fatigue, brain fog, muscle and joint pain, cardiac and pulmonary issues, or other factors related to their acute COVID-19 event).
Key inclusion criteria (4 listed)
- Enrolled in Huntington Hospital\'s Long Covid Recovery Clinic
- Documented previous infection with SARS-CoV2
- Symptoms suggestive of post-acute sequelae of SARS-CoV2 (including but not limited to chronic fatigue, brain fog, muscle and joint pain, cardiac and pulmonary issues, or other factors related to their acute COVID-19 event)
- Signed Informed Consent Form
Key exclusion criteria (3 listed)
- No documented positive SARS-CoV2 serologies
- No post-acute sequelae of SARS-CoV2 symptomatology
- Incarcerated
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Correlation of symptomatology with inflammatory profiles in patients with Post-Acute Sequelae of SARS-CoV2 (PASC)
Time frame: From onset of infection to 24 months
Do patient symptoms correlate with abnormalities in inflammatory profiles?
Identification of immunologic and inflammatory features of PASC based on results of immunologic and inflammatory assays
Time frame: From onset of infection to 24 months
Are there abnormalities in immunologic and inflammatory assays unique to PASC?
Evaluation and delineation of the pathologic pathways and long-term effects of SARS-CoV2 infection
Time frame: From onset of infection to 60 months
What are the pathological pathways and long-term effects of SARS-CoV2?
Identification of risks factor for PASC
Time frame: From onset of infection to 24 months
What are the risk factors for PASC?
Identification of potential sites of therapeutic intervention to ameliorate symptomatology of PASC
Time frame: From onset of infection to 60 months
Are there potential sites of therapeutic intervention to relieve the symptoms of PASC?
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for COVID-19
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Active, not recruiting
Intervention to Address Disparate Mental Health Consequences of COVID-19 Pandemic on Latinx and African Newcomers
Mental Health Issue, Mental Health Disorder
Recruiting
Home-Based Exercise Tele-Rehabilitation After COVID-19
Post SARS-CoV2 (COVID-19)
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Kimberly Shriner, MD principal investigator
Huntington Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of COVID-19, run by Huntington Memorial Hospital at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 20 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Correlation of symptomatology with inflammatory profiles in patients with Post-Acute Sequelae of SARS-CoV2 (PASC) (time frame: From onset of infection to 24 months). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Oct 2026.